Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Sangamo Therapeutics, Inc. is a publicly traded biotechnology company focused on developing genomic medicines that aim to treat serious genetic and neurological diseases. The company operates within the biotechnology and gene therapy industries, with core capabilities spanning genome editing, gene regulation, and gene replacement therapies. Its programs are designed to address conditions with high unmet medical need, including rare monogenic diseases and central nervous system disorders.
Founded in 1995, Sangamo was an early pioneer of zinc finger protein (ZFP) technology, one of the first programmable DNA-binding platforms used for targeted genome modification. Over time, the company expanded its approach to include AAV-based gene therapy and ZFP transcription factor (ZFP-TF) platforms for epigenetic regulation. While several early programs were discontinued following clinical or strategic reassessments, Sangamo has evolved into a more focused clinical-stage organization centered on select late-stage and mid-stage assets, particularly in Fabry disease and neurological disorders.
Business Operations
Sangamo generates value primarily through the research and development of proprietary genomic medicine candidates and through strategic collaborations with larger biopharmaceutical companies. Its operations are organized around three core technology platforms: ZFP Genome Editing, ZFP Transcriptional Regulation, and AAV Gene Therapy, which collectively support its internal pipeline and partnered programs. Revenue historically has been derived mainly from collaboration agreements, upfront payments, milestones, and research funding rather than product sales.
The company conducts the majority of its research and development activities internally, supported by a network of contract manufacturing organizations and global clinical trial sites. Sangamo has entered into major collaborations with established pharmaceutical partners, including Pfizer, Biogen, and Sanofi, to advance programs in hemophilia, neurology, and lysosomal storage disorders, respectively. Some partnerships have been restructured or concluded as programs matured or strategic priorities shifted, reflecting the high-risk nature of clinical-stage biotechnology development.
Strategic Position & Investments
Sangamo’s strategic direction is centered on advancing a streamlined portfolio of clinical-stage genomic medicines while leveraging partnerships to offset development risk and capital requirements. A key priority is the advancement of isaralgagene civaparvovec (ST-920), an AAV-based gene therapy candidate for Fabry disease, which has emerged as the company’s lead wholly owned asset following encouraging clinical data and the discontinuation of certain partnered programs.
In parallel, Sangamo continues to invest in neurological disease programs utilizing its ZFP-TF platform, including partnered assets targeting conditions such as ALS and other neurodegenerative disorders. The company has not pursued large-scale acquisitions in recent years, instead favoring capital preservation, pipeline prioritization, and selective investment in platform technologies. This strategy reflects a broader industry trend toward focus and partnership-driven development in genomic medicine.
Geographic Footprint
Sangamo is headquartered in Brisbane, California, within the United States, and conducts the majority of its corporate and research operations there. Its clinical development activities extend internationally, with trial sites and regulatory engagement across North America and Europe, reflecting the global nature of rare disease research and patient recruitment.
Through its collaborations with multinational pharmaceutical companies, Sangamo maintains indirect operational and commercial reach across additional regions, including Western Europe and select global markets. While the company does not maintain a large international office footprint, its technologies and clinical programs have global applicability and are designed with worldwide regulatory pathways in mind.
Leadership & Governance
Sangamo was co-founded by Edward Lanphier, who played a central role in establishing the company’s early leadership in genome editing technologies. The current leadership team emphasizes scientific rigor, disciplined capital allocation, and strategic focus on programs with the highest probability of clinical and regulatory success.
- Sandy Macrae – Chief Executive Officer
- David McKeon – Chief Financial Officer
- Kurt A. A. Kruger – Chief Medical Officer
- Chris Hollowood – Chief Technical Officer
- Rajesh Pande – Executive Vice President, Corporate Development
The leadership’s stated strategic vision centers on translating Sangamo’s long-standing genomic expertise into clinically and commercially viable therapies, while maintaining strong governance practices consistent with U.S. public company standards and SEC filings requirements.